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six months pre-index (“baseline period”); and age<65 for six months post-index 
(“study period”). Baseline characteristics and study period prescription  
drug initiations (requiring six-month washout) by PA status (Iowa PA policy 
begun 5/24/2010) were compared between the two cohorts in each state. Logistic 
models were used to calculate risk-adjusted study period drug initiation rates, 
controlling for baseline characteristics. RESULTS: Iowa patients had significantly 
(p<.05) higher rates of anxiety and lower baseline health care costs 2010 versus 
2009 (n=9,429 vs. n=8,443). Missouri patients were significantly younger, had 
higher rates of mental disorders, and higher baseline health care costs in 2010 
versus 2009 (n=19,541 vs. n=13,083). In Iowa, risk-adjusted initiations  
of antidepressants (2009-2010) without PA increased significantly (17.8% vs. 
19.4%); initiations decreased significantly for: duloxetine (2.0% vs.1.6%), other 
antidepressants with PA (4.2% vs. 1.2%), and atypical antipsychotics without  
PA (7.5% vs. 6.7%). In Missouri, initiations increased significantly (2009-2010)  
for antidepressants without PA (21.4% vs. 24.2%) and atypical antipsychotics 
without PA (10.0% vs. 10.8%); the duloxetine initiation rate was not significantly 
different (2.9% vs. 2.7%). CONCLUSIONS: The Iowa Medicaid PA for duloxetine 
reduced the rate of duloxetine initiations, and did not increase atypical 
antipsychotic use.  
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OBJECTIVES: Compare antipsychotic adherence and costs among patients with 
schizophrenia identified as “high-risk” for future antipsychotic nonadherence by 
the Assessment for Quality Improvement and Risk Evaluation (QI-RE) tool to 
controls not identified as high-risk. QI-RE is a software tool developed by Janssen 
Scientific Affairs, LLC and Boston Health Economics, Inc. that applies adapted 
published regression equations to pharmacy and medical claims data to assess 
schizophrenic patients’ risk for future antipsychotic nonadherence. METHODS: 
Retrospective analysis using pharmacy, medical, and eligibility data from 
Humana Medicare Advantage patients diagnosed with schizophrenia (ICD-9-CM 
295.xx) having continuous enrollment from 1/1/2010-12/31/2011. QI-RE and data 
from 2010 were used to identify patients in the highest-risk quartile for future 
antipsychotic nonadherence (high-risk cohort). The remaining patients in the 
study population (lower-risk) acted as the control cohort. Antipsychotic 
adherence (proportion of days covered [PDC]), persistence (14 day gap allowance) 
and health care costs during 2011 were compared across both cohorts. Student’s 
t-tests and chi-square tests were used for continuous and categorical variables, 
respectively. RESULTS: Relative to the control cohort (n=3,867), the high-risk 
cohort (n=1,139) was younger (mean age 54.6 vs. 55.4 years, p<0.041) and had 
more African Americans (26.0% vs. 17.8%, p<0.001). During follow-up, mean PDC 
was 0.48 versus 0.81 (p<0.001); persistence was 119.3 versus 144.3 days (p<0.001); 
antipsychotic pharmacy costs were $1,950 versus $3,933 (p<0.001); and, 
psychiatric-related medical costs were $4,938 versus $4,452 (p=0.192) for high-
risk and control cohorts, respectively. CONCLUSIONS: Patients identified as 
high-risk for antipsychotic nonadherence by QI-RE had poorer adherence, 
shorter persistency, and lower antipsychotic pharmacy costs during the follow-
up period relative to controls. These results support the potential utility of QI-RE 
for quality improvement initiatives related to antipsychotic adherence in 
patients with schizophrenia.  
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OBJECTIVES: Examine hospitalization rates and costs for cohorts of patients with 
schizophrenia identified as ‘high-risk’ by the Assessment for Quality Improvement 
and Risk Evaluation (QI-RE) tool compared to cohorts not designated as ‘high-risk’. 
QI-RE is a software tool developed by Janssen Scientific Affairs, LLC and Boston 
Health Economics, Inc. that applies adapted published regression equations to 
pharmacy and medical claims to assess patients’ risk for future hospitalizations. 
METHODS: Retrospective analysis using pharmacy, medical, and eligibility claims 
data from Humana Medicare Advantage patients diagnosed with schizophrenia 
(ICD-9-CM 295.xx) having continuous enrollment from 1/1/2010-12/31/2011. QI-RE 
and data from 2010 were used to identify cohorts of patients in the highest-risk 
quartiles for future All-Cause (ACH) and Psychiatric-Related (PRH) hospitalization. 
For each hospitalization outcome, separate control cohorts were constructed with 
patients from the three lower-risk quartiles. Hospitalizations and costs during 1-
year follow-up (2011) were compared between high-risk and control cohorts. 
RESULTS: High-risk cohorts had a higher proportion of females (58.0% vs. 48.6% in 
ACH, p<.0001; 57.6% vs. 48.7% in PRH, p<.0001) and Caucasians (77.6% vs. 72.4% in 
ACH, p=.0042; 77.5% vs. 72.4% in PRH, p=.0048) relative to respective controls. During 
follow-up, the proportion with ≥1 hospitalization (56.5% vs. 26.0% in ACH, p<.0001; 
49.7% vs. 21.7% in PRH, p<.0001), mean number of hospitalizations (2.7 vs. 1.0 in 
ACH, p<.0001; 1.7 vs. 0.6 in PRH, p<.0001), and mean total health care costs ($23,203 
vs. $12,841 in ACH, p<.0001; $23,213 vs. $12,835 in PRH, p<.0001) were significantly 
higher for each QI-RE cohort relative to respective controls. CONCLUSIONS: Patients 
identified as high-risk by QI-RE experienced higher rates of hospitalizations and 
higher health care costs in the follow-up period relative to controls. These results 
support the potential utility of this population health tool for quality improvement 
and cost avoidance efforts in managing patients with schizophrenia.  
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OBJECTIVES: To describe characteristics of adult Medicaid beneficiaries with 
schizophrenia initiated with Paliperidone Palmitate (PP) and assess the 
relationships between such characteristics and treatment continuity. METHODS: 
Adult Medicaid enrollees with schizophrenia, 30+ days of treatment with PP, and 
6 months continuous enrollment prior to the first PP claim in 2009-2011 were 
identified in the MarketScan® Medicaid Multi-State Database. Exclusion criteria 
included dual eligible coverage, mental health carve-out, or a claim for Risperdal 
Consta at index. Characteristics were compared between three groups created 
based on days continuous with PP (Group A: ≥151, B: 91-150, C: 31-90). The first 
gap of 14+ days between the days covered by one claim and the date of the next 
claim was defined as the end of continuous therapy. Cox proportional hazards 
regression identified factors associated with PP treatment continuity over 6 
months. RESULTS: A total of 725 patients comprised the sample, of which 339 
(47%) were continuous with PP for ≥151 days. Overall, the average age for the 
sample was 39 years, 64% were male, 41% white. Pre-index characteristics for 
groups A vs C were significantly different with respect to the number of unique 
3-digit ICD-9 diagnosis codes (mean/SD: 8.8/7.3 vs 10.8/8.9; p=0.004), number of 
unique psychiatric diagnostic categories (2.8/2.0 vs 3.5/2.2; p<0.001), number of 
unique antipsychotic agents (1.6/1.0 vs 1.8/1.1; p=0.028), diagnosed bipolar 
disorder (17% vs 27%; p=0.003), diagnosed depression (20% vs 30%; p=0.006), 
diagnosed alcohol abuse (9% vs 15%; p=0.029) and percent of patients with any 
psychiatric hospitalization (30% vs 42%; p=0.002). Cox proportional hazards 
regression models (saturated & stepwise) did not identify any factors 
significantly associated with treatment continuity. CONCLUSIONS: Relative to 
patients continuous with PP therapy for longer than 151 days, patients with 31-
90 days of continuous therapy had a more complex profile of mental health 
comorbidites and pre-index resource utilization.  
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OBJECTIVES: Was to determine the percentage of drug interactions’ risk in 
elderly population receiving three or more drugs at the same time, also and 
degree of risk of severe, moderate and mild interactions. METHODS: This study 
was retrospectively-observational. The study included 50 patients of both 
genders, aged at least 65 years, who were treated in the first half 2012th in the 
Health Center Novi Sad which prescribed three or more drugs. Three sources of 
information about possible drug interactions were used: www.drugs.com, British 
National Formulary (BNF) and SPC of drug. RESULTS: The study included a total 
of 50 patients with mean age of 73.62 years. According to the number of possible 
drug interactions, most of them were from BNF (n = 204 or 45.43% compared to 
the number of possible drug combinations), then www.drugs.com (n = 203 or 
45.21%) and from SPC source were significantly less (n = 150 or 33.40%). In 
relation to the degree of relevancy of drug interactions, according to the source 
www.drugs.com, the incidence of serious interactions was 3%, 29% moderate 
and 13% mild. Out of 50 patients analyzed, only in 9 patients (18%) were found 
complete compatibility in the number of interactions in all three data sources. A 
significantly higher number of interactions were at the level of 
pharmacodynamic (167 or 77.68%). CONCLUSIONS: With the increasing number 
of taken drugs at the same time, increases the total number of interactions with 
a correlation coefficient of 0.71. Publications and Internet could provide useful 
information of drug interactions, but we could not say what else is important in 
a particular patient. This research was supported by Provincial Secretariat for 
Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science and Technological 
Development, Republic of Serbia project No 41012.  
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BACKGROUND: Medication errors is a major issue that every health care setting 
keeps addressing because it has a direct bearing on the safety of the patients. 
The results across the globe have demonstrated that the drug interactions 
continue to be a leading cause of errors. OBJECTIVES: The stduy was carried out 
with the obejctive of detecting the medication errors in the inpatients and profile 
them. METHODS: This study was carried out in an inpatient setting of a private 
tertiary care hospital. Medication errors were identified from patients' files, 
using Micromedex on PDA. 17 errors were fixed as the becnmark and 
assessments were done using this. RESULTS: The results are based on data 
